Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Cardiovascular Drugs and Therapy
Erschienen in: Cardiovascular Drugs and Therapy 4/2015

01.08.2015 | ORIGINAL ARTICLE

Metabolic Syndrome: Does it Differ Between Women and Men?

verfasst von: Yogita Rochlani, Naga Venkata Pothineni, Jawahar L. Mehta

Erschienen in: Cardiovascular Drugs and Therapy | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Cardiovascular disease represents a massive healthcare burden worldwide. Gender differences in the pathophysiology, presentation and prognosis of cardiovascular disease have been described in the literature. Metabolic syndrome, characterized by a cluster of metabolic abnormalities is associated with increased risk for type 2 diabetes mellitus and atherosclerotic cardiovascular disease. With the global obesity epidemic, the prevalence of metabolic syndrome is rising rapidly in the developed as well as developing world. However, there is considerable variation in the prevalence based on geography, age, sex and, definition used for diagnosis. Data on gender related differences in metabolic syndrome is relatively scarce. Here, we aim to review the gender differences in epidemiology and pathophysiology of metabolic syndrome as well as its individual components. Knowledge of gender differences in metabolic syndrome can help design gender specific preventative and therapeutic strategies that will have a positive impact on overall population health.
Literatur
1.
Grundy SM, Hansen B, Smith Jr SC, Cleeman JI, Kahn RA, American Heart Association, National Heart, Lung, and Blood Institute, American Diabetes Association. Clinical management of metabolic syndrome: report of the American heart association/national heart, lung, and blood institute/American diabetes association conference on scientific issues related to management. Arterioscler Thromb Vasc Biol. 2004;24(2):e19–24.CrossRefPubMed
2.
3.
Wenger NK. Women and coronary heart disease: a century after herrick: understudied, underdiagnosed, and undertreated. Circulation. 2012;126(5):604–11.CrossRefPubMed
4.
Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595–607.CrossRefPubMed
5.
DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14(3):173–94.CrossRefPubMed
6.
Lemieux I, Pascot A, Couillard C, Lamarche B, Tchernof A, Almeras N, et al. Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation. 2000;102(2):179–84.CrossRefPubMed
7.
Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med. 1989;149(7):1514–20.CrossRefPubMed
8.
Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24(4):683–9.CrossRefPubMed
9.
Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15(7):539–53.CrossRefPubMed
10.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285(19):2486–97.CrossRef
11.
Alberti KG, Zimmet P, Shaw J. Metabolic syndrome—a new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med. 2006;23(5):469–80.CrossRefPubMed
12.
Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American heart association/national heart, lung, and blood institute scientific statement. Circulation. 2005;112(17):2735–52.CrossRefPubMed
13.
Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; National heart, Lung, and blood institute; American heart association; World heart federation; International atherosclerosis society; and International association for the study of obesity. Circulation. 2009;120(16):1640–5.CrossRefPubMed
14.
Lin CC, Liu CS, Li CI, Lin WY, Lai MM, Lin T, et al. The relation of metabolic syndrome according to five definitions to cardiovascular risk factors—a population-based study. BMC Public Health. 2009;9:484.PubMedCentralCrossRefPubMed
15.
Ervin RB. Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United states, 2003–2006. Natl Health Stat Rep. 2009;13:1–7.
16.
Meigs JB, Wilson PW, Nathan DM, D’Agostino RBS, Williams K, Haffner SM. Prevalence and characteristics of the metabolic syndrome in the San Antonio heart and Framingham offspring studies. Diabetes. 2003;52(8):2160–7.CrossRefPubMed
17.
Mozumdar A, Liguori G. Persistent increase of prevalence of metabolic syndrome among U.S. adults: NHANES III to NHANES 1999–2006. Diabetes Care. 2011;34(1):216–9.PubMedCentralCrossRefPubMed
18.
Miller JM, Kaylor MB, Johannsson M, Bay C, Churilla JR. Prevalence of metabolic syndrome and individual criterion in US adolescents: 2001–2010 national health and nutrition examination survey. Metab Syndr Relat Disord. 2014;12(10):527–32.CrossRefPubMed
19.
Loucks EB, Rehkopf DH, Thurston RC, Kawachi I. Socioeconomic disparities in metabolic syndrome differ by gender: evidence from NHANES III. Ann Epidemiol. 2007;17(1):19–26.CrossRefPubMed
20.
Cherry CO, Serieux E, Didier M, Nuttal ME, Schuster RJ. Prevalence of risk factors for the metabolic syndrome in the middle income Caribbean nation of St. Lucia. Adv Prev Med. 2014;2014:501972.PubMedCentralCrossRefPubMed
21.
Ishii S, Tanaka T, Akishita M, Ouchi Y, Tuji T, Iijima K, et al. Metabolic syndrome, Sarcopenia and role of sex and age: cross-sectional analysis of Kashiwa cohort study. PLoS One. 2014;9(11), e112718.PubMedCentralCrossRefPubMed
22.
Sobko T, Trindade D, Lao QX, Wong M, Io TK, Wa CK, et al. Men in Macau SAR have higher prevalence in metabolic syndrome and among related metabolic components: a cross-sectional Macau health survey. BMC Public Health. 2014;14:1065.PubMedCentralCrossRefPubMed
23.
Yu S, Guo X, Yang H, Zheng L, Sun Y. An update on the prevalence of metabolic syndrome and its associated factors in rural northeast China. BMC Public Health. 2014;14:877, 2458-14-877.
24.
Xi B, He D, Hu Y, Zhou D. Prevalence of metabolic syndrome and its influencing factors among the Chinese adults: the china health and nutrition survey in 2009. Prev Med. 2013;57(6):867–71.PubMedCentralCrossRefPubMed
25.
Mabry RM, Reeves MM, Eakin EG, Owen N. Gender differences in prevalence of the metabolic syndrome in gulf cooperation council countries: a systematic review. Diabet Med. 2010;27(5):593–7.CrossRefPubMed
26.
Erem C, Hacihasanoglu A, Deger O, Topbas M, Hosver I, Ersoz HO, et al. Prevalence of metabolic syndrome and associated risk factors among Turkish adults: Trabzon MetS study. Endocrine. 2008;33(1):9–20.CrossRefPubMed
27.
Athyros VG, Bouloukos VI, Pehlivanidis AN, Papageorgiou AA, Dionysopoulou SG, Symeonidis AN, et al. The prevalence of the metabolic syndrome in Greece: the MetS-Greece multicentre study. Diabetes Obes Metab. 2005;7(4):397–405.CrossRefPubMed
28.
Balkau B, Charles MA, Drivsholm T, Borch-Johnsen K, Wareham N, Yudkin JS, et al. Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab. 2002;28(5):364–76.PubMed
29.
Dallongeville J, Cottel D, Arveiler D, Tauber JP, Bingham A, Wagner A, et al. The association of metabolic disorders with the metabolic syndrome is different in men and women. Ann Nutr Metab. 2004;48(1):43–50.CrossRefPubMed
30.
Levine DA, Lewis CE, Williams OD, Safford MM, Liu K, Calhoun DA, et al. Geographic and demographic variability in 20-year hypertension incidence: the CARDIA study. Hypertension. 2011;57(1):39–47.PubMedCentralCrossRefPubMed
31.
Ong KL, Tso AW, Lam KS, Cheung BM. Gender difference in blood pressure control and cardiovascular risk factors in Americans with diagnosed hypertension. Hypertension. 2008;51(4):1142–8.CrossRefPubMed
32.
Denton KM, Hilliard LM, Tare M. Sex-related differences in hypertension: seek and ye shall find. Hypertension. 2013;62(4):674–7.CrossRefPubMed
33.
Rossi P, Frances Y, Kingwell BA, Ahimastos AA. Gender differences in artery wall biomechanical properties throughout life. J Hypertens. 2011;29(6):1023–33.CrossRefPubMed
34.
Hilliard LM, Mirabito KM, Denton KM. Unmasking the potential of the angiotensin AT2 receptor as a therapeutic target in hypertension in men and women: what we know and what we still need to find out. Clin Exp Pharmacol Physiol. 2013;40(8):542–50.CrossRefPubMed
35.
Harris MI, Eastman RC, Cowie CC, Flegal KM, Eberhardt MS. Comparison of diabetes diagnostic categories in the U.S. population according to the 1997 american diabetes association and 1980–1985 world health organization diagnostic criteria. Diabetes Care. 1997;20(12):1859–62.CrossRefPubMed
36.
Glucose tolerance and mortality: comparison of WHO and American diabetes association diagnostic criteria. The DECODE study group. European diabetes epidemiology group. Diabetes epidemiology: Collaborative analysis of diagnostic criteria in Europe. Lancet. 1999;354(9179):617–21.
37.
Unwin N, Shaw J, Zimmet P, Alberti KG. Impaired glucose tolerance and impaired fasting Glycaemia: the current status on definition and intervention. Diabet Med. 2002;19(9):708–23.CrossRefPubMed
38.
Varlamov O, Bethea CL, Roberts Jr CT. Sex-specific differences in lipid and glucose metabolism. Front Endocrinol (Lausanne). 2015;5:241.
39.
Aldhoon-Hainerova I, Zamrazilova H, Dusatkova L, Sedlackova B, Hlavaty P, Hill M, et al. Glucose homeostasis and insulin resistance: prevalence, gender differences and predictors in adolescents. Diabetol Metab Syndr. 2014;6(1):100. eCollection 2014.PubMedCentralCrossRefPubMed
40.
Barrett-Connor E, Ferrara A. Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men. The Rancho Bernardo study. Diabetes Care. 1998;21(8):1236–9.CrossRefPubMed
41.
Goff Jr DC, Bertoni AG, Kramer H, Bonds D, Blumenthal RS, Tsai MY, et al. Dyslipidemia prevalence, treatment, and control in the Multi-Ethnic Study of Atherosclerosis (MESA): gender, ethnicity, and coronary artery calcium. Circulation. 2006;113(5):647–56.CrossRefPubMed
42.
Johnson JL, Slentz CA, Duscha BD, Samsa GP, McCartney JS, Houmard JA, et al. Gender and racial differences in lipoprotein subclass distributions: the STRRIDE study. Atherosclerosis. 2004;176(2):371–7.CrossRefPubMed
43.
Bittner V. Perspectives on dyslipidemia and coronary heart disease in women. J Am Coll Cardiol. 2005;46(9):1628–35.CrossRefPubMed
44.
Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the global burden of disease study 2013. Lancet. 2014;384(9945):766–81.CrossRefPubMed
45.
Beydoun MA, Wang Y. Gender-ethnic disparity in BMI and waist circumference distribution shifts in US adults. Obesity (Silver Spring). 2009;17(1):169–76.CrossRef
46.
Garawi F, Devries K, Thorogood N, Uauy R. Global differences between women and men in the prevalence of obesity: is there an association with gender inequality? Eur J Clin Nutr. 2014;68(10):1101–6.CrossRefPubMed
47.
Kahn HS, Bullard KM, Barker LE, Imperatore G. Differences between adiposity indicators for predicting all-cause mortality in a representative sample of United States non-elderly adults. PLoS One. 2012;7(11), e50428.PubMedCentralCrossRefPubMed
48.
Pradhan AD. Sex differences in the metabolic syndrome: implications for cardiovascular health in women. Clin Chem. 2014;60(1):44–52.CrossRefPubMed
49.
Meyer MR, Clegg DJ, Prossnitz ER, Barton M. Obesity, insulin resistance and diabetes: sex differences and role of oestrogen receptors. Acta Physiol (Oxf). 2011;203(1):259–69.CrossRef
50.
Brand JS, van der Tweel I, Grobbee DE, Emmelot-Vonk MH, van der Schouw YT. Testosterone, sex hormone-binding globulin and the metabolic syndrome: a systematic review and meta-analysis of observational studies. Int J Epidemiol. 2011;40(1):189–207.CrossRefPubMed
51.
Bhasin S, Jasjua GK, Pencina M, D’Agostino RS, Coviello AD, Vasan RS, et al. Sex hormone-binding globulin, but not testosterone, is associated prospectively and independently with incident metabolic syndrome in men: the Framingham heart study. Diabetes Care. 2011;34(11):2464–70.PubMedCentralCrossRefPubMed
52.
Janssen I, Powell LH, Crawford S, Lasley B, Sutton-Tyrrell K. Menopause and the metabolic syndrome: the study of women’s health across the nation. Arch Intern Med. 2008;168(14):1568–75.PubMedCentralCrossRefPubMed
53.
Kupelian V, Hayes FJ, Link CL, Rosen R, McKinlay JB. Inverse association of testosterone and the metabolic syndrome in men is consistent across race and ethnic groups. J Clin Endocrinol Metab. 2008;93(9):3403–10.PubMedCentralCrossRefPubMed
54.
Duskova M, Pospisilova H. The role of non-aromatizable testosterone metabolite in metabolic pathways. Physiol Res. 2011;60(2):253–61.PubMed
55.
Bjorntorp P. The origins and consequences of obesity. Diab Ciba Found Sym. 1996;201:68–80. discussion 80–9, 188–93.
56.
Kalyani RR, Franco M, Dobs AS, Ouyang P, Vaidya D, Bertoni A, et al. The association of endogenous sex hormones, adiposity, and insulin resistance with incident diabetes in postmenopausal women. J Clin Endocrinol Metab. 2009;94(11):4127–35.PubMedCentralCrossRefPubMed
57.
Laaksonen DE, Niskanen L, Punnonen K, Nyyssonen K, Tuomainen TP, Valkonen VP, et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care. 2004;27(5):1036–41.CrossRefPubMed
58.
Li C, Ford ES, Li B, Giles WH, Liu S. Association of testosterone and sex hormone-binding globulin with metabolic syndrome and insulin resistance in men. Diabetes Care. 2010;33(7):1618–24.PubMedCentralCrossRefPubMed
59.
Ding EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2006;295(11):1288–99.CrossRefPubMed
60.
Vikan T, Schirmer H, Njolstad I, Svartberg J. Low testosterone and sex hormone-binding globulin levels and high estradiol levels are independent predictors of type 2 diabetes in men. Eur J Endocrinol. 2010;162(4):747–54.CrossRefPubMed
61.
Ding EL, Song Y, Manson JE, Hunter DJ, Lee CC, Rifai N, Buring JE, Gaziano JM, Liu S. Sex Hormone–Binding globulin and risk of type 2 diabetes in women and men. N Engl J Med. 2009; 2015/02;361(12):1152–63.
62.
Haring R, Volzke H, Spielhagen C, Nauck M, Wallaschofski H. The role of sex hormone-binding globulin and testosterone in the risk of incident metabolic syndrome. Eur J Prev Cardiol. 2013;20(6):1061–8.CrossRefPubMed
63.
Daka B, Rosen T, Jansson PA, Larsson CA, Rastam L, Lindblad U. Low sex hormone-binding globulin is associated with hypertension: a cross-sectional study in a Swedish population. BMC Cardiovasc Disord. 2013;13:30.PubMedCentralCrossRefPubMed
64.
Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial. JAMA. 2002;288(3):321–33.CrossRefPubMed
65.
Velez LM, Motta AB. Association between polycystic ovary syndrome and metabolic syndrome. Curr Med Chem. 2014;21(35):3999–4012.CrossRefPubMed
66.
Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90(4):1929–35.CrossRefPubMed
67.
Hillman JK, Johnson LN, Limaye M, Feldman RA, Sammel M, Dokras A. Black women with Polycystic Ovary Syndrome (PCOS) have increased risk for metabolic syndrome and cardiovascular disease compared with white women with PCOS [corrected]. Fertil Steril. 2014;101(2):530–5.CrossRefPubMed
68.
Essah PA, Nestler JE. The metabolic syndrome in polycystic ovary syndrome. J Endocrinol Investig. 2006;29(3):270–80.CrossRef
69.
Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56(14):1113–32.CrossRefPubMed
70.
Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care. 2005;28(7):1769–78.CrossRefPubMed
71.
Kuk JL, Ardern CI. Age and sex differences in the clustering of metabolic syndrome factors: association with mortality risk. Diabetes Care. 2010;33(11):2457–61.PubMedCentralCrossRefPubMed
72.
Guize L, Thomas F, Pannier B, Bean K, Jego B, Benetos A. All-cause mortality associated with specific combinations of the metabolic syndrome according to recent definitions. Diabetes Care. 2007;30(9):2381–7.CrossRefPubMed
73.
Hari P, Nerusu K, Veeranna V, Sudhakar R, Zalawadiya S, Ramesh K, et al. A gender-stratified comparative analysis of various definitions of metabolic syndrome and cardiovascular risk in a multiethnic U.S. population. Metab Syndr Relat Disord. 2012;10(1):47–55.PubMedCentralCrossRefPubMed
74.
Beltrán-Sánchez H, Harhay MO, Harhay MM, McElligott S. Prevalence and trends of metabolic syndrome in the adult U.S. population, 1999–2010. J Am Coll Cardiol. 2013;62(8):697–703.PubMedCentralCrossRefPubMed
75.
76.
Heiss G, Snyder ML, Teng Y, Schneiderman N, Llabre MM, Cowie C, et al. Prevalence of metabolic syndrome among Hispanics/Latinos of diverse background: the Hispanic community health study/study of Latinos. Diabetes Care. 2014;37(8):2391–9.PubMedCentralCrossRefPubMed
77.
Scuteri A, Najjar SS, Morrell CH, Lakatta EG, Cardiovascular Health Study. The metabolic syndrome in older individuals: prevalence and prediction of cardiovascular events: the cardiovascular health study. Diabetes Care. 2005;28(4):882–7.CrossRefPubMed
78.
Ford ES, Li C, Zhao G. Prevalence and correlates of metabolic syndrome based on a harmonious definition among adults in the US. J Diabetes. 2010;2(3):180–93.CrossRefPubMed
79.
Yang JJ, Yoon HS, Lee SA, Choi JY, Song M, Han S, et al. Metabolic syndrome and sex-specific socio-economic disparities in childhood and adulthood: the Korea national health and nutrition examination surveys. Diabet Med. 2014;31(11):1399–409.CrossRefPubMed
80.
Podang J, Sritara P, Narksawat K. Prevalence and factors associated with metabolic syndrome among a group of Thai working population: a cross sectional study. J Med Assoc Thai. 2013;96 Suppl 5:S33–41.PubMed
81.
Deepa M, Farooq S, Datta M, Deepa R, Mohan V. Prevalence of metabolic syndrome using WHO, ATPIII and IDF definitions in Asian Indians: the Chennai urban rural epidemiology study (CURES-34). Diabetes Metab Res Rev. 2007;23(2):127–34.CrossRefPubMed
82.
Deedwania PC, Gupta R, Sharma KK, Achari V, Gupta B, Maheshwari A, et al. High prevalence of metabolic syndrome among urban subjects in India: a multisite study. Diabetes Metab Syndr. 2014;8(3):156–61.CrossRefPubMed
83.
El Brini O, Akhouayri O, Gamal A, Mesfioui A, Benazzouz B. Prevalence of metabolic syndrome and its components based on a harmonious definition among adults in Morocco. Diabetes Metab Syndr Obes. 2014;7:341–6.PubMedCentralPubMed
84.
Malik M, Razig SA. The prevalence of the metabolic syndrome among the multiethnic population of the United Arab Emirates: a report of a national survey. Metab Syndr Relat Disord. 2008;6(3):177–86.CrossRefPubMed
85.
Al-Daghri NM, Alkharfy KM, Al-Attas OS, Khan N, Alfawaz HA, Alghanim SA, et al. Gender-dependent associations between socioeconomic status and metabolic syndrome: a cross-sectional study in the adult Saudi population. BMC Cardiovasc Disord. 2014;14:51.PubMedCentralCrossRefPubMed
86.
Vernay M, Salanave B, de Peretti C, Druet C, Malon A, Deschamps V, et al. Metabolic syndrome and socioeconomic status in France: the French nutrition and health survey (ENNS, 2006–2007). Int J Public Health. 2013;58(6):855–64.CrossRefPubMed
87.
Maggi S, Noale M, Gallina P, Bianchi D, Marzari C, Limongi F, et al. Metabolic syndrome, diabetes, and cardiovascular disease in an elderly Caucasian cohort: the Italian longitudinal study on aging. J Gerontol A Biol Sci Med Sci. 2006;61(5):505–10.CrossRefPubMed
Metadaten
Titel
Metabolic Syndrome: Does it Differ Between Women and Men?
verfasst von
Yogita Rochlani
Naga Venkata Pothineni
Jawahar L. Mehta
Publikationsdatum
01.08.2015
Verlag
Springer US
Erschienen in
Cardiovascular Drugs and Therapy / Ausgabe 4/2015
Print ISSN: 0920-3206
Elektronische ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-015-6593-6

Weitere Artikel der Ausgabe 4/2015

Cardiovascular Drugs and Therapy 4/2015 Zur Ausgabe

ORIGINAL ARTICLE

The Challenges of Prevention, Diagnosis and Treatment of Ischemic Heart Disease in Women

ORIGINAL ARTICLE

Gender Differences in Cardiovascular Drugs

ORIGINAL ARTICLE

The Role of 17β-Estradiol in Myocardial Hypertrophy in Females in the Presence and Absence of Hypertension

EDITORIAL

Women and Heart Disease; A Focus Issue

ORIGINAL ARTICLE

Vasotonic Angina as a Cause of Myocardial Ischemia in Women

ORIGINAL ARTICLE

Gender-Related Differences in Atherosclerosis

Neu im Fachgebiet Kardiologie

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Strenge Blutdruckeinstellung lohnt auch im Alter noch

30.04.2024 Arterielle Hypertonie Nachrichten

Ältere Frauen, die von chronischen Erkrankungen weitgehend verschont sind, haben offenbar die besten Chancen, ihren 90. Geburtstag zu erleben, wenn ihr systolischer Blutdruck < 130 mmHg liegt. Das scheint selbst für 80-Jährige noch zu gelten.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Dihydropyridin-Kalziumantagonisten können auf die Nieren gehen

30.04.2024 Hypertonie Nachrichten

Im Vergleich zu anderen Blutdrucksenkern sind Kalziumantagonisten vom Diyhdropyridin-Typ mit einem erhöhten Risiko für eine Mikroalbuminurie und in Abwesenheit eines RAS-Blockers auch für ein terminales Nierenversagen verbunden.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise